| |
Group 1
|
Group 2
|
|---|
| |
(n = 322)
|
(n = 125)
|
|---|
|
Age (years)
|
38.6 ± 5.4
|
38.9 ± 5.4
|
|
BMI** (kg/m2)
|
24.0 ± 4.9
|
24.1 ± 4.6
|
|
DHEA (ng/dL)
|
469.2 ± 289.8
|
467.9 ± 308.9
|
|
DHEAS (μg/dL)
|
253.5 ± 189.0
|
371.6 ± 233.4
|
|
Total testosterone (ng/dL)
|
26.0 ± 13.7
|
33.7 ± 23.5
|
|
Free testosterone (pg/mL)
|
2.0 ± 1.5
|
2.6 ± 1.8
|
|
TSH (μIU/mL)
|
1.9 ± 1.2
|
1.9 ± 1.0
|
|
Thyroid antibodies
|
22.0%
|
16.0%
|
|
Anti-adrenal antibodies
|
0.3%
|
0%
|
|
Anti-ovarian antibodies
|
9.3%
|
6.4%
|
|
Antinuclear antibodies (ANA)
|
13.0%
|
7.2%
|
|
Antiphopholipid antibodies (APA)
|
14.6%
|
14.4%
|
|
Gammopathy
|
32.0%
|
36.0%
|
|
Immune system activation***
|
59.0%
|
59.2%
|
- *Values are presented as means ± standard deviation or as percentages. Patient characteristics did not differ between both groups except for DHEAS (P < 0.001), total testosterone (P < 0.001) and free testosterone (P < 0.01), all three the consequence of DHEA supplementation for women with LFOR between baseline evaluation and IVF cycle start. For further detail, see text.
- Percentages among antibodies represent percentages of patients with positive antibody tests.
- **BMI, body mass index.
- ***Defined by presence of at least 1 positive laboratory test.
